AbbVie Inc. $ABBV Shares Sold by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB trimmed its holdings in AbbVie Inc. (NYSE:ABBV) by 15.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 110,575 shares of the company’s stock after selling 19,800 shares during the period. AbbVie accounts for about 2.4% of Rhenman & Partners Asset Management AB’s portfolio, making the stock its 8th biggest holding. Rhenman & Partners Asset Management AB’s holdings in AbbVie were worth $25,265,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. Sumitomo Life Insurance Co. lifted its position in shares of AbbVie by 25.7% in the fourth quarter. Sumitomo Life Insurance Co. now owns 19,314 shares of the company’s stock valued at $4,413,000 after buying an additional 3,954 shares during the last quarter. Wealthspire Advisors LLC lifted its position in shares of AbbVie by 16.0% in the fourth quarter. Wealthspire Advisors LLC now owns 58,434 shares of the company’s stock valued at $13,352,000 after buying an additional 8,053 shares during the last quarter. Tillman Hartley LLC lifted its position in shares of AbbVie by 3.6% in the fourth quarter. Tillman Hartley LLC now owns 3,496 shares of the company’s stock valued at $799,000 after buying an additional 121 shares during the last quarter. Allianz SE lifted its position in shares of AbbVie by 2.7% in the fourth quarter. Allianz SE now owns 97,245 shares of the company’s stock valued at $22,220,000 after buying an additional 2,596 shares during the last quarter. Finally, Macquarie Group Ltd. lifted its position in shares of AbbVie by 5.5% in the fourth quarter. Macquarie Group Ltd. now owns 986,044 shares of the company’s stock valued at $224,893,000 after buying an additional 51,559 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ABBV. Canaccord Genuity Group raised their price objective on AbbVie from $262.00 to $265.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $240.00 price objective on shares of AbbVie in a research report on Thursday, April 30th. Morgan Stanley raised their price objective on AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, June 7th. Finally, Piper Sandler increased their target price on AbbVie from $294.00 to $298.00 and gave the stock an “overweight” rating in a research note on Thursday, May 14th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and a consensus price target of $253.43.

AbbVie Trading Up 1.2%

Shares of NYSE ABBV opened at $227.54 on Friday. The firm has a market cap of $402.02 billion, a P/E ratio of 112.09, a price-to-earnings-growth ratio of 0.69 and a beta of 0.32. AbbVie Inc. has a 1-year low of $181.73 and a 1-year high of $244.81. The business’s 50 day moving average is $211.05 and its 200-day moving average is $219.07.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. The company had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same quarter last year, the company earned $2.46 earnings per share. Analysts forecast that AbbVie Inc. will post 14.3 EPS for the current year.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said nine-year CLL14 data showed venetoclax plus obinutuzumab delivered durable progression-free survival in previously untreated chronic lymphocytic leukemia, strengthening the case for the drug’s long-term commercial value. AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
• Positive Sentiment: Investors are also focused on AbbVie’s broader pipeline and franchise strength, with commentary pointing to Skyrizi and Rinvoq continuing to drive revenue growth, which supports the company’s outlook beyond legacy Humira. Will Skyrizi & Rinvoq Continue to Drive AbbVie’s Topline Through 2026?
• Neutral Sentiment: Several market commentaries described AbbVie as a defensive, high-quality compounder, but noted the shares may not be cheap at current levels, which suggests valuation may temper upside even with strong fundamentals. AbbVie: A Defensive Compounder Worth Holding, But Not A Bargain Buy
• Negative Sentiment: One article highlighted regulatory risk around AbbVie’s fast-acting neurotoxin TrenibotE after an FDA complete response letter, which could delay a potential growth driver if development setbacks persist. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.